Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
Upturn AI SWOT - About
XTL Biopharmaceuticals Ltd ADR (XTLB)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
08/14/2025: XTLB (1-star) has a low Upturn Star Rating. Not recommended to BUY.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
0 Analysts rated it
Very few follow this stock; limited insights, higher-risk early investing.
Analysis of Past Performance
Type Stock | Historic Profit 13.61% | Avg. Invested days 30 | Today’s Advisory WEAK BUY |
Upturn Star Rating | Upturn Advisory Performance  3.0 | Stock Returns Performance  2.0 |
| Profits based on simulation | Last Close 08/14/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 10.22M USD | Price to earnings Ratio - | 1Y Target Price 30 |
Price to earnings Ratio - | 1Y Target Price 30 | ||
Volume (30-day avg) - | Beta 0.99 | 52 Weeks Range 0.86 - 3.05 | Updated Date 06/29/2025 |
52 Weeks Range 0.86 - 3.05 | Updated Date 06/29/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -0.3 |
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin -227.72% | Operating Margin (TTM) -200.49% |
Management Effectiveness
Return on Assets (TTM) -24.74% | Return on Equity (TTM) -26.83% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 9117987 | Price to Sales(TTM) 22.67 |
Enterprise Value 9117987 | Price to Sales(TTM) 22.67 | ||
Enterprise Value to Revenue 20.22 | Enterprise Value to EBITDA 16.88 | Shares Outstanding 8813850 | Shares Floating 451886180 |
Shares Outstanding 8813850 | Shares Floating 451886180 | ||
Percent Insiders 41.29 | Percent Institutions 2.92 |
Upturn AI SWOT
XTL Biopharmaceuticals Ltd ADR
Company Overview
History and Background
XTL Biopharmaceuticals Ltd. is a biopharmaceutical company focused on the discovery, development, and commercialization of pharmaceutical products for the treatment of autoimmune diseases and infectious diseases. Founded in 1993, it has evolved through various clinical trials and partnerships.
Core Business Areas
- Autoimmune Diseases: Developing therapies for autoimmune conditions, targeting specific immune pathways to reduce inflammation and improve patient outcomes.
- Infectious Diseases: Researching and developing novel treatments for infectious diseases, with a focus on addressing unmet medical needs in this area.
Leadership and Structure
The company is led by a management team with experience in drug development and commercialization. The organizational structure is typically composed of research and development, clinical operations, and administrative functions.
Top Products and Market Share
Key Offerings
- hCDR1: hCDR1 is XTL's lead drug candidate, an immunomodulatory compound being developed for the treatment of autoimmune diseases, including psoriasis and multiple sclerosis. There is currently no market share data or revenue information publicly available for this product, as it is still in clinical development. Competitors include companies developing biologics and small molecule inhibitors for these diseases.
- Opaganib (proposed): Opaganib is a novel, orally-available sphingosine kinase-2 (SK2) selective inhibitor. RedHill Biopharma is the license holder of Opaganib. XTL may have other future products in infectious disease. Competitors include companies developing antiviral drugs.
Market Dynamics
Industry Overview
The biopharmaceutical industry is characterized by intense competition, high regulatory hurdles, and significant investment in research and development. The industry is constantly evolving with new technologies and therapies.
Positioning
XTL Biopharmaceuticals is a smaller player in the biopharmaceutical industry, focusing on niche markets within autoimmune and infectious diseases. Its competitive advantage lies in its innovative approaches to these diseases.
Total Addressable Market (TAM)
The TAM for autoimmune diseases and infectious diseases is substantial, estimated at billions of dollars annually. XTL Biopharmaceuticals is positioned to capture a share of this market with successful development and commercialization of its drug candidates.
Upturn SWOT Analysis
Strengths
- Innovative drug candidates
- Experienced management team
- Focus on niche markets
Weaknesses
- Limited financial resources
- Dependence on clinical trial success
- Small size compared to competitors
Opportunities
- Partnerships with larger pharmaceutical companies
- Expansion into new therapeutic areas
- Positive clinical trial results
Threats
- Competition from established pharmaceutical companies
- Regulatory hurdles
- Clinical trial failures
Competitors and Market Share
Key Competitors
- ABBV
- BMY
- MRK
- GILD
Competitive Landscape
XTL Biopharmaceuticals faces significant competition from larger, more established pharmaceutical companies. Its success depends on its ability to innovate and execute its development programs effectively.
Growth Trajectory and Initiatives
Historical Growth: Historical growth has been driven by clinical trial progress and partnerships.
Future Projections: Future growth is dependent on the successful development and commercialization of its drug candidates. Analyst estimates are limited due to the company's size and stage of development.
Recent Initiatives: Recent initiatives may include advancing clinical trials, seeking partnerships, and exploring new therapeutic targets.
Summary
XTL Biopharmaceuticals is a small biopharmaceutical company with promising drug candidates in autoimmune and infectious diseases. Its success hinges on positive clinical trial results and strategic partnerships, but it faces significant competition and financial constraints. The company's future depends on effectively navigating regulatory hurdles and securing funding for ongoing research and development. Financial status can not be reliably rated as it is a foreign company.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company Website
- SEC Filings
- Third-party Financial Data Providers
- Public Press Releases
Disclaimers:
The data provided is for informational purposes only and should not be considered investment advice. Market share data is estimated and may not be precise. Financial data may be limited or unavailable for certain periods. Investment in XTL Biopharmaceuticals Ltd ADR involves significant risks, including the risk of loss of investment.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About XTL Biopharmaceuticals Ltd ADR
Exchange NASDAQ | Headquaters - | ||
IPO Launch date 2005-09-01 | CEO - | ||
Sector Healthcare | Industry Biotechnology | Full time employees 10 | Website https://www.xtlbio.com |
Full time employees 10 | Website https://www.xtlbio.com | ||
XTL Biopharmaceuticals Ltd., a biopharmaceutical company, engages in the acquisition and development of pharmaceutical drugs for the treatment of autoimmune diseases in Israel. Its lead drug candidate is hCDR1, which is a Phase II-ready asset for the treatment of systemic lupus erythematosus and Sjogren's syndrome. The company has a licensing agreement with Yeda Research and Development Company Limited for the research, development, and commercialization of hCDR1 for various indications. The company was formerly known as Xenograft Technologies Ltd. and changed its name to XTL Biopharmaceuticals Ltd. in July 1995. XTL Biopharmaceuticals Ltd. was incorporated in 1993 and is headquartered in Ramat Gan, Israel.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.